Inhibition of PCSK9 in familial hypercholesterolaemia

被引：4
|
作者：
Sijbrands, Eric J. G. [1 ,2 ]
机构：
[1] Erasmus MC, Pharmacol Vasc & Metab Dis sect, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus MC, Dept Cardiol & Internal Med, Cardiovasc Genet Sect, NL-3000 CA Rotterdam, Netherlands
来源：
LANCET | 2012年 / 380卷 / 9836期
关键词：
APOLIPOPROTEIN-B; CONTROLLED-TRIAL; LDL CHOLESTEROL; DOUBLE-BLIND; STATIN; ATHEROSCLEROSIS; MIPOMERSEN; EZETIMIBE; EFFICACY; THERAPY;
D O I：
10.1016/S0140-6736(12)60814-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6 / 7
页数：2
相关论文
共 50 条
  • [41] Nine paths to PCSK9 inhibition
    Asher Mullard
    Nature Reviews Drug Discovery, 2017, 16 : 299 - 301
  • [42] Nine paths to PCSK9 inhibition
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (05) : 299 - U11
  • [43] Inhibition of ApoCIII: the next PCSK9?
    Moens, Sophie J. Bernelot
    van Capelleveen, Julian C.
    Stroes, Erik S. G.
    CURRENT OPINION IN LIPIDOLOGY, 2014, 25 (06) : 418 - 422
  • [44] PCSK9 inhibition to combat hyperlipidaemia
    Kang, Seema
    LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (05): : 366 - 366
  • [45] PCSK9-Hemmung – ein UpdateUpdate on PCSK9 inhibition
    Julius L. Katzmann
    Florian Custodis
    Stephan H. Schirmer
    Ulrich Laufs
    Herz, 2022, 47 : 196 - 203
  • [46] Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
    Raal, Frederick J.
    Honarpour, Narimon
    Blom, Dirk J.
    Hovingh, G. Kees
    Xu, Feng
    Scott, Rob
    Wasserman, Scott M.
    Stein, Evan A.
    Investigators, T. E. S. L. A.
    LANCET, 2015, 385 (9965): : 341 - 350
  • [47] MUTATIONS IN LDLR, APOB, PCSK9 AND APOE GENES CONTRIBUTE TO THE GENETIC SPECTRUM OF FAMILIAL HYPERCHOLESTEROLAEMIA IN THE NORTH OF ENGLAND
    Johnston, L.
    Potter, A.
    Carey, P.
    Luvai, A.
    McKenna, P.
    Weaver, J.
    Pattman, S.
    Kamaruddin, S.
    Arutchevelam, V.
    Anderson, M.
    Burns, M.
    Hopper, N.
    Sutton, R.
    McAnulty, C.
    Curtis, A.
    Neely, R.
    ATHEROSCLEROSIS, 2018, 275 : E79 - E79
  • [48] New perspectives in the treatment of hypercholesterolaemia since the availability of PCSK9 inhibitors
    Pinto, X.
    Sarasa, I
    HIPERTENSION Y RIESGO VASCULAR, 2019, 36 (04): : 213 - 220
  • [49] Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation
    Kuehl, Michael
    Binner, Christian
    Jozwiak, Joanna
    Fischer, Julia
    Hahn, Jochen
    Addas, Alaeldin
    Dinov, Boris
    Garbade, Jens
    Hindricks, Gerhard
    Borger, Michael
    PLOS ONE, 2019, 14 (01):
  • [50] THE EFFECT OF PCSK9 INHIBITION IN FAMILIAL DYSBETALIPOPROTEINEMIA (TYPE III HYPERLIPOPROTEINEMIA): 4 CASES
    Busygina, Kristina
    Waldmann, Elisa
    Parhofer, Klaus
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 1759 - 1759
12345